Literature DB >> 17006910

HCV core expression in hepatocytes protects against autoimmune liver injury and promotes liver regeneration in mice.

Hiroki Kawamura1, Sugantha Govindarajan, Fred Aswad, Keigo Machida, Michael M C Lai, Vicky M-H Sung, Gunther Dennert.   

Abstract

Hepatitis C virus (HCV) infection causes acute and chronic liver disease often leading to liver cirrhosis and hepatocellular carcinoma. Numerous studies have shown that despite induction of virus specific immunity, a curative response is often not attained; this has led to the hypothesis that HCV genes modulate immunity, thereby enabling chronic infections. This study examined the effects on immune-mediated liver injury in transgenic mice expressing core protein throughout the body and bone marrow chimeras expressing core protein in either the lymphoid compartment or liver parenchyma. Presence of core protein in the liver parenchyma but not in lymphoid cells protects from autoimmune hepatitis induced by mitogen concanavalin A (ConA). Consistent with this observation, core transgenic hepatocytes are relatively resistant to death induced by anti-Fas antibody and tumor necrosis factor alpha (TNFalpha). This protective effect is associated with preferential activation of signal transducer and activation of transcription factor 3 (STAT3) versus STAT1 in livers of ConA-injected animals. In agreement with this effect of core protein on the Janus kinase (JAK)-STAT signaling pathway, transgenic mice accelerate liver regeneration after partial hepatectomy but are not protected from hepatocyte death. In conclusion, HCV core inhibits STAT1 and stimulates STAT3 activation, which protects infected hepatocytes from attack by the cell-mediated immune system and promotes their proliferation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17006910     DOI: 10.1002/hep.21360

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  14 in total

1.  IL-22 is involved in liver regeneration after hepatectomy.

Authors:  Xiaodan Ren; Bin Hu; Lisa M Colletti
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-10-29       Impact factor: 4.052

Review 2.  Enhanced apoptosis in post-liver transplant hepatitis C: effects of virus and immunosuppressants.

Authors:  Eu Jin Lim; Ruth Chin; Peter W Angus; Joseph Torresi
Journal:  World J Gastroenterol       Date:  2012-05-14       Impact factor: 5.742

Review 3.  Liver immune-pathogenesis and therapy of human liver tropic virus infection in humanized mouse models.

Authors:  Moses T Bility; Feng Li; Liang Cheng; Lishan Su
Journal:  J Gastroenterol Hepatol       Date:  2013-08       Impact factor: 4.029

4.  Activation of innate immunity (NK/IFN-gamma) in rat allogeneic liver transplantation: contribution to liver injury and suppression of hepatocyte proliferation.

Authors:  Kezhen Shen; Shu-Sen Zheng; Ogyi Park; Hua Wang; Zhaoli Sun; Bin Gao
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-02-21       Impact factor: 4.052

Review 5.  Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma.

Authors:  Patrick Arbuthnot; Liam-Jed Thompson
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

Review 6.  Nucleolus, ribosomes, and cancer.

Authors:  Lorenzo Montanaro; Davide Treré; Massimo Derenzini
Journal:  Am J Pathol       Date:  2008-06-26       Impact factor: 4.307

Review 7.  Immune responses during acute and chronic infection with hepatitis C virus.

Authors:  Shigeaki Ishii; Margaret James Koziel
Journal:  Clin Immunol       Date:  2008-06-02       Impact factor: 3.969

8.  Liver regeneration is suppressed in alcoholic cirrhosis: correlation with decreased STAT3 activation.

Authors:  Norio Horiguchi; Edward J N Ishac; Bin Gao
Journal:  Alcohol       Date:  2007-06       Impact factor: 2.405

Review 9.  Influence of host resistance on viral adaptation: hepatitis C virus as a case study.

Authors:  Anne Plauzolles; Michaela Lucas; Silvana Gaudieri
Journal:  Infect Drug Resist       Date:  2015-04-07       Impact factor: 4.003

Review 10.  Mouse models for the study of HCV infection and virus-host interactions.

Authors:  Heidi Barth; Eric Robinet; T Jake Liang; Thomas F Baumert
Journal:  J Hepatol       Date:  2008-04-14       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.